ArticleActa neuropathologica2018
cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV".
Abstract readLetter
In one paragraph
Article in Acta neuropathologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 487 papers, 4 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
487citing papers in PubMed, 4 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
487 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Pooled it
- Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2.International journal of clinical oncology · 2024Guideline
- Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis.Journal of neuro-oncology · 2023Pooled it
- Imaging features associated with H3 K27-altered and H3 G34-mutant gliomas: a narrative systematic review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Pooled it
- Dual Immune Check Point Blockade inJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Comprehensive Molecular Analysis in NRG Oncology/RTOG 9813: A Phase 3 Study of Radiation and Temozolomide Versus Radiation and BCNU/CCNU in Anaplastic Astrocytoma.International journal of radiation oncology, biology, physics · 2025Trial
- Response Rate and Molecular Correlates to Encorafenib and Binimetinib in BRAF-V600E Mutant High-Grade Glioma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Redox Regulation in Glioblastoma: Mechanisms, Biomarkers, and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Imaging diagnosis of adult-type diffuse gliomas in the era of WHO CNS5 and cIMPACT-NOW updates 8-11: a narrative review.Japanese journal of radiology · 2026Review
- The intersection of chemokine signaling with the hallmarks of cancer in glioblastoma.Journal of neuro-oncology · 2026Review
- Diagnostic Pitfalls of Oligodendroglioma-like Morphology: Integrated Reappraisal of 23 Non-Oligodendroglial Central Nervous System Tumors.Diagnostics (Basel, Switzerland) · 2026Article
- Molecularly diagnosed glioblastoma: clinical presentation and outcomes.Journal of neuro-oncology · 2026Article
- Article
- Validation of proposed cIMPACT-NOW update 12 molecular grading criteria for IDH-mutant astrocytoma.Acta neuropathologica · 2026Article
- Loss of Neuropeptide Y Signaling Accompanies the Neural-to-Mesenchymal Transcriptional Transition in Glioblastoma: A Multi-Scale Transcriptomic Analysis.International journal of molecular sciences · 2026Article
- Immunohistochemistry as a tool for identifying EGFR amplification in CNS tumors.Brain pathology (Zurich, Switzerland) · 2026Article
- Distinguishing Molecular and Histologic Glioblastomas Using Multiparametric MRI-Based Habitat Analysis.Korean journal of radiology · 2026Article
- Metaproteomic profiling reveals viral proteins and associated host proteomic alterations in glioblastoma.Scientific reports · 2026Article
- Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations.Journal of neuro-oncology · 2026Article
- Report of treatment intensity and survival outcomes in older patients with glioblastoma diagnosed according to WHO CNS 5 classification.Journal of neuro-oncology · 2026Observational
427 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
12 authors.
Daniel J BratDepartment of Pathology, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Ward Building, 3-140, 303 E. Chicago Ave, Chicago, IL, 60611, USA. Daniel.brat@northwestern.edu.
Kenneth AldapeLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.
Howard ColmanDepartment of Neurosurgery, Huntsman Cancer Center, University of Utah, Salt Lake City, UT, USA.
Eric C HollandDepartment of Neurosurgery, Fred Hutchinson Cancer Center, University of Washington, Seattle, WA, USA.
David N LouisDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Robert B JenkinsDepartment of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
B K Kleinschmidt-DeMastersDepartment of Pathology, University of Colorado School of Medicine, Aurora, CO, USA.
Arie PerryDepartment of Pathology, University of California San Francisco, San Francisco, CA, USA.
Guido ReifenbergerDepartment of Neuropathology, Heinrich Heine University, Düsseldorf, Germany.
Roger StuppMalnati Brain Tumor Institute, Robert H. Lurie Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Andreas von DeimlingDepartment of Neuropathology, Institute of Pathology, University of Heidelberg, Heidelberg, Germany.
Michael WellerDepartment of Neurology, University Hospital and University of Zurich, Zurich, Switzerland.
Funding
Genomic Biomarkers of CancerZIABC011850 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ALDAPE, KENNETH · 2019 to 2025
$5.1MMolecular Target Variation Across Environments and at Margins of GlioblastomaR01CA176659 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI BRAT, DANIEL J, HADJIPANAYIS, CONSTANTINOS GEORGE · 2013 to 2017
$2.3MNCI NIH HHS R01 CA176659
Abstract
PubMed holds no abstract for this paper.
Indexed as
Central Nervous System NeoplasmsErbB ReceptorsGlioblastomaHumansIsocitrate DehydrogenaseMutationPromoter Regions, GeneticTelomeraseWorld Health OrganizationEGFR protein, humanErbB ReceptorsIsocitrate DehydrogenaseTelomeraseTERT protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.